Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Acute Myeloid Leukaemia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Acute myeloid leukaemia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute myeloid leukaemia pipeline landscape is provided which includes the disease overview and Acute myeloid leukaemia treatment guidelines.

The assessment part of the report embraces, in depth Acute myeloid leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute myeloid leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute myeloid leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Acute myeloid leukaemia.

Acute myeloid leukaemia Emerging Drugs Chapters

This segment of the Acute myeloid leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute myeloid leukaemia Emerging Drugs

Volasertib: Boehringer Ingelheim

Volasertib is an investigational, selective and potent inhibitor of enzymes called Polo-like kinases (Plks). Plk1, the best understood of the five known Plks, has an important role in cell division. Inhibition of Plk1 by volasertib* results in cell cycle arrest with subsequent induction of apoptosis (programmed cell death). Volasertib is currently being evaluated in clinical trials for acute myeloid leukaemia and is one of several late-stage (Phase III) compounds that Boehringer Ingelheim is currently evaluating in clinical trials for the treatment of cancer.

BST-236: BioSight

Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. The drug is currently in phase II stage of of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

Uproleselan: GlycoMimetics

GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. The drug is currently in phase III stage of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

Pevonedistat: Takeda

Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor. In pre-clinical studies, the inhibition of NAE by pevonedistat blocked the modification of select proteins, which resulted in disruption of cell cycle progression and cell survival, leading to cancer cell death.

Major Players in Acute myeloid leukaemia

There are approx. 150+ key companies which are developing the therapies for Acute myeloid leukaemia. The companies which have their Acute myeloid leukaemia drug candidates in the most advanced stage, i.e. phase III include, Boehringer Ingelheim.

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute myeloid leukaemia drugs?
• How many Acute myeloid leukaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute myeloid leukaemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute myeloid leukaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute myeloid leukaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• BioSight
• GlycoMimetics
• Takeda
• Sumitomo Dainippon Pharma
• Menarini Group
• Telios Pharma, Inc.
• Kartos Therapeutics
• ImmunoGen, Inc.
• H3 Biomedicine Inc.
• GEMoaB GmbH
• Shijiazhuang Yiling Pharmaceutical
• Intellia Therapeutics
• Chongqing Precision Biotech Co., Ltd
• Innovent Biologics
• Betta Pharmaceuticals Co., Ltd.
• Maxinovel Pty., Ltd.
• Argenx
• Astex Pharmaceuticals
• Hanmi Pharmaceutical Company Limited
• ALX Oncology Inc.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Novartis
• Fujifilm Pharmaceuticals U.S.A., Inc.
• I-Mab Biopharma Co. Ltd.
• Akeso
• Gilead Sciences
• Kronos Bio
• Celgene
• Polaris Group
• Ryvu Therapeutics SA
• Kura Oncology, Inc.
• Sanofi
• Amgen
• BioTheryX, Inc.
• Celyad Oncology SA
• Arog Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp.
• Actinium Pharmaceuticals
• Moleculin Biotech
• Karyopharm Therapeutics Inc
• GlaxoSmithKline

Key Products

• Volasertib
• IBI188
• BST-236
• Uproleselan
• BTX-A51
• NTLA-5001
• MK-0482
• AMG 176
• KPT-9274
• CD123 CAR-T cells
• GSK3326595
• Iomab-B
• Crenolanib besylate
• Liposomal Annamycin
• CYAD-02
• ASTX727
• ARGX-110
• KO-539
• TJ011133
• SAR443579
• Magrolimab
• Sabatolimab
• FF-10101-01
• Entospletinib
• evorpacept
• SKI-G-801
• XY0206
• RVU120
• ADI-PEG 20
• CC-91633
• Mitoxantrone Hydrochloride liposome injection
• GEM333
• IMGN632
• Pevonedistat
• HM43239
• DSP 5336
• MEN 1703
• AK117
• TL-895
• KRT-232
• MRX2843
• MAX-40279-01

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/jfnyxd